Mutant IDH1: an immunotherapeutic target in tumors
The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mut...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
07 Jan 2015
|
| In: |
OncoImmunology
Year: 2014, Jahrgang: 3, Heft: 12 |
| ISSN: | 2162-402X |
| DOI: | 10.4161/2162402X.2014.974392 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.4161/2162402X.2014.974392
|
| Verfasserangaben: | Theresa Schumacher, Lukas Bunse, Wolfgang Wick, and Michael Platten |
| Zusammenfassung: | The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mutation-specific CD4+ antitumor T cell response in patients and a syngeneic tumor model in MHC-humanized mice. |
|---|---|
| Beschreibung: | Gesehen am 20.07.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 2162-402X |
| DOI: | 10.4161/2162402X.2014.974392 |